Research and development
Just twenty years ago, the medical use of the cannabis plant was still in its infancy. The companies THC Pharm and Bionorica ethics were the first in Germany to recognize the far-reaching potential of this plant for treatment in many indication areas. Since then, continuous investment in research and development has made it possible to steadily gain new insights into both the active ingredients as well as their pharmacological and medical potential. Through the merger of THC Pharm and Bionorica ethics under the umbrella of C³-Holding GmbH, the synergy potential of the two manufacturers could be exploited for the purpose of a focused research strategy.
Bionorica ethics in Neumarkt/Upper Palatinate isolates dronabinol in pharmaceutical quality and cannabidiol in food quality from medical cannabis flowers. THC Pharm, based in Frankfurt am Main, synthesizes dronabinol and cannabidiol in GMP-compliant pharmaceutical quality in high-tech chemical processes. In addition to synthesizing THC and CBD for therapeutic purposes, THC Pharm is the market leader in the production of high-purity cannabinoid reference substances for analytical and other laboratory applications. Two completely different manufacturing processes and two different production sites for cannabinoids were thus united under the umbrella of C³.